Program 52: Kidney Cancer

肾癌项目 项目摘要/摘要 DF/HCC肾癌计划对肾脏的分子基础进行创新性的基础研究 肿瘤。当前资助期内的科学努力侧重于确定有意义的生物标记物 早期发现和预后，疾病生物学的基本机制，新的治疗靶点 不同的肾癌人群，并改进了用于初步验证这些发现的临床前模型。 该计划在肾癌的基于机制的分类和治疗方面取得了显著进展， 以患者预后的显著改善和2019年诺贝尔医学奖授予 长期担任孢子联合领袖的W.Kaelin DFCI因其对细胞感知机制的开创性发现而获奖 氧气。该计划处于有利地位，可以在解决关键问题方面发挥主导作用，这些问题将是 在不久的将来，人们越来越重视肾癌的研究。 该方案的42名成员(29名小学和13名中学)代表6个DF/CC机构和9个学术机构 各部门。2019年，经同行审查的赠款用于该方案的直接成本为210万美元 来自NCI的170万美元和其他赞助商的170万美元。在本资助期内，主要计划 成员发表了612篇与癌症相关的论文。其中，40%是机构间的，21%是机构内的 方案协作，47%是两个或更多DF/CC成员之间的方案间协作。 为了实现该计划的使命，我们对CCSG的下一次资助提出了以下具体目标 阶段：1)确定和验证肾癌的新靶点，并建立临床前模型以测试新的 代理商；2)利用计划基础设施促进药物开发并识别分子和 预后和治疗反应的生物学预测指标；以及3)确保该计划服务于 马萨诸塞州(我们的CCSG集水区)和全国通过发展癌症预防和 早期发现战略、社区教育和对该领域未来领导者的培训。要执行这些操作 旨在，我们将充分利用DF/HCC的协作基础设施、核心设施、临床试验系统、 以及社区参与和癌症研究培训的结构化流程。

Kidney Cancer Program Project Summary / Abstract The DF/HCC Kidney Cancer Program performs innovative basic research into the molecular basis of kidney tumors. Scientific efforts within the current funding period focused on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology, novel therapeutic targets for the various kidney cancer populations, and improved preclinical models for preliminary validation of these findings. The Program has made notable advances in mechanism-based classification and treatment of kidney cancers, rewarded by marked improvements in patient outcomes and with the 2019 Nobel Prize in Medicine awarded to longstanding SPORE co-leader W.KaelinDFCI for his seminal discovery of the mechanism by which cells sense oxygen. The Program is well positioned for a leading role in addressing critical questions that will be points of increasing emphasis in kidney cancers in the near future. The Program’s 42 members (29 primary and 13 secondary) represent six DF/HCC institutions and 9 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $2.1 million in direct costs from the NCI and $1.7 million from other sponsors. During the current funding period, primary Program members published 612 cancer-relevant papers. Of these, 40% were inter-institutional, 21% were intra- programmatic, and 47% were inter-programmatic collaborations between two or more DF/HCC members. In order to achieve the Program mission, we propose the following Specific Aims over the next CCSG funding period: 1) Identify and validate novel targets in kidney cancer and establish preclinical models to test new agents; 2) Leverage Program infrastructure to facilitate drug development and to identify molecular and biological predictors of prognosis and response to therapy; and 3) Ensure that the Program serves Massachusetts (our CCSG catchment area) and the nation through the development of cancer prevention and early detection strategies, community education, and training of future leaders in the field. To execute these Aims, we will take full advantage of DF/HCC’s collaborative infrastructure, core facilities, clinical trial systems, and structured processes for community engagement and cancer research training.